Funding for this research was provided by:
Astellas Pharma Inc. Investigator Initiated Study Grant
Article History
First Online: 23 November 2018
Compliance with Ethical Standards
:
: This work was supported by an Astellas Pharma Inc. Investigator Initiated Study Grant. Financial support included funding for: (1) genotyping of CYP3A5 rs776746 (CYP3A5*3) and MDR1 rs1045642 (MDR1 C3435T), (2) the trial coordinator, (3) pharmacokinetic studies, (4) standardized meals during pharmacokinetic studies, (5) Prograf<sup>®</sup> and Advagraf<sup>®</sup>, and (6) laboratory tests performed as part of the study protocol.
: A. Vathsala has received honoraria from Astellas Pharma Inc. for talks given at scientific meetings. W.P. Yau and C.W.T. Loh declare that they have no conflict of interest.
: This study was approved by the National Healthcare Group Domain Specific Review Board (NHG DSRB ref: 2012/01026) and granted a Clinical Trial Certificate (certificate number: CTC1300029) by the Health Sciences Authority, Singapore. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.